

Form PTO-1449 (modified)		Atty. Docket No. CLFR:158US	Serial No. 10/663,573
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant J. Vernon Knight et al.	
		Filing Date: September 16, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
AS	A1	5,049,388	11/17/91	Knight et al.	424	450	07/21/89
	A2	5,422,344	06/06/95	Priel et al.	514	50	05/08/90
	A3	5,552,156	11/03/96	Burke	424	450	03/22/95
	A4	5,736,156	04/07/98	Burke	424	450	04/12/96
	A5	5,958,378	11/28/99	Waldrep et al.	424	45	10/16/96
	A6	6,090,407	07/18/00	Knight et al.	424	450	11/23/97
▼	A7	6,346,233	02/12/02	Knight et al.	424	45	07/17/00

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
AS	B1	DB 4430593C2	08/20/94	Germany	Abstract
	B2	WO 9318751	03/23/93	WIPO	English
	B3	WO 9426253	05/16/94	WIPO	English
	B4	WO 9605821	08/18/95	WIPO	Abstract
▼	B5	WO 9619199	12/20/95	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
AS	C1	"Chiron submits new drug application for pulminiq; inhaled form of cyclosporine could be first immunosuppressant indicated for chronic lung-transplant rejection," www.drugs.com/nda/pulminiq_041014.html 9/14/06
AS	C2	Abang et al., "The clinical pharmacology of topoisomerase I inhibitors," <i>Sem Hematol</i> , 35:13-21, 1998.

25695214.1

EXAMINER: /Aradhana Sasan/ DATE CONSIDERED: 01/17/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. CLFR:158US	Serial No. 10/663,573
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant J. Vernon Knight et al.	
		Filing Date: September 16, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Int.	Ref. Des.	Citation
AS	C3	Ahmed et al., "Influence of route of administration on [3h]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies," <i>Cancer Chemother Pharmacol.</i> , 39:122-130, 1996.
	C4	Anderson, "Delivery systems for immunomodulatory proteins and peptides," <i>BioDrugs</i> , 7:51-65, 1997.
	C5	Burckart et al., "Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients," <i>Pharmaceutical Research</i> , 20:252-256, 2003.
	C6	Chourpa et al., "Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA," <i>Biochem</i> , 37:7284-7291, 1998.
	C7	Fresta et al., "Evaluation and optimization of liposomes as delivery device for methotrexate," <i>Pharmacie</i> , 47:926-929, 1992.
	C8	Garcia-Carbonero et al., "Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins," <i>Clin. Cancer Res.</i> , 8:641-661, 2002.
	C9	Giovanella et al., "Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin," <i>Cancer Res.</i> , 51:3052-3055, 1991.
	C10	Hallman et al., "Inositol supplementation in premature infants with respiratory distress syndrome," <i>N. Eng. J. Med.</i> , 326:1233-1239, 1992.
	C11	Hausheer et al., "Karenitecins: a novel, potent class of oral highly lipophilic topo I inhibitors," <i>Proc. Annu. Meet. Am. Assoc. Cancer Res.</i> , 38:A1526, 1997.
	C12	Hertzberg et al., "Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity," <i>J. Medic. Chem.</i> , 32:715-720, 1989.
	C13	Hochster et al., "Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen," <i>J. Clin. Oncol.</i> , 12:553-559, 1994.
	C14	Iacono et al., "Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans," <i>Eur. Respir. J.</i> , 23:384-390, 2004.
	C15	Kim et al., "Pharmacodynamics of insulin in polyethylene glycol-coated liposomes," <i>Int. J. Pharm.</i> , 180:75-81, 1999.
▼	C16	Knight et al., "New approaches in aerosol drug delivery for the treatment of asthma," in Allergy and Allergic Diseases, Kay (ed), Blackwell Publications, Oxford, England, L730-741. (<u>DATE UNKNOWN</u>)

25695214.1

EXAMINER: /Aradhana Sasan/ DATE CONSIDERED: 01/17/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)